{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T19:16:46Z","timestamp":1773515806795,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,14]]},"DOI":"10.7759\/cureus.105219","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T13:18:16Z","timestamp":1773494296000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review"],"prefix":"10.7759","author":[{"given":"Suneha","family":"Shelke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rusheeth R","family":"Thummalapally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3928\/02793695-20210816-01","article-title":"Treatment-resistant depression: approaches to treatment","volume":"59","author":"Kverno KS","year":"2021","unstructured":"Kverno KS, Mangano E. Treatment-resistant depression: approaches to treatment. J Psychosoc Nurs Ment Health Serv. 2021, 59:7-11. 10.3928\/02793695-20210816-01","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly EJ","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, et al.. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019, 76:893-903. 10.1001\/jamapsychiatry.2019.1189","journal-title":"JAMA Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11070856","article-title":"Therapeutic potentials of ketamine and esketamine in obsessive-compulsive disorder (OCD), substance use disorders (SUD) and eating disorders (ED): a review of the current literature","volume":"11","author":"Martinotti G","year":"2021","unstructured":"Martinotti G, Chiappini S, Pettorruso M, et al.. Therapeutic potentials of ketamine and esketamine in obsessive-compulsive disorder (OCD), substance use disorders (SUD) and eating disorders (ED): a review of the current literature. Brain Sci. 2021, 11:856. 10.3390\/brainsci11070856","journal-title":"Brain Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2018.01475","article-title":"Psychedelics, meditation, and self-consciousness","volume":"9","author":"Milli\u00e8re R","year":"2018","unstructured":"Milli\u00e8re R, Carhart-Harris RL, Roseman L, Trautwein FM, Berkovich-Ohana A. Psychedelics, meditation, and self-consciousness. Front Psychol. 2018, 9:1475. 10.3389\/fpsyg.2018.01475","journal-title":"Front Psychol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14344.1","article-title":"Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide","volume":"7","author":"Duman RS","year":"2018","unstructured":"Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Res. 2018, 7:10.12688\/f1000research.14344.1","journal-title":"F1000Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/biom13091411","article-title":"Esketamine inhibits cocaine-seeking behaviour subsequent to various abstinence conditions in rats","volume":"13","author":"Wydra K","year":"2023","unstructured":"Wydra K, Witek K, Suder A, Filip M. Esketamine inhibits cocaine-seeking behaviour subsequent to various abstinence conditions in rats. Biomolecules. 2023, 13:1411. 10.3390\/biom13091411","journal-title":"Biomolecules"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.18101123","article-title":"A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial","volume":"176","author":"Dakwar E","year":"2019","unstructured":"Dakwar E, Nunes EV, Hart CL, et al.. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry. 2019, 176:923-930. 10.1176\/appi.ajp.2019.18101123","journal-title":"Am J Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000338","article-title":"Mindfulness-based relapse prevention for substance use disorders: a systematic review and meta-analysis","volume":"11","author":"Grant S","year":"2017","unstructured":"Grant S, Colaiaco B, Motala A, Shanman R, Booth M, Sorbero M, Hempel S. Mindfulness-based relapse prevention for substance use disorders: a systematic review and meta-analysis. J Addict Med. 2017, 11:386-396. 10.1097\/ADM.0000000000000338","journal-title":"J Addict Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241254834","article-title":"Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems","volume":"38","author":"Gent EM","year":"2024","unstructured":"Gent EM, Bryan JW, Cleary MA, et al.. Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems. J Psychopharmacol. 2024, 38:541-550. 10.1177\/02698811241254834","journal-title":"J Psychopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2021.21030277","article-title":"Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder","volume":"179","author":"Grabski M","year":"2022","unstructured":"Grabski M, McAndrew A, Lawn W, et al.. Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry. 2022, 179:152-162. 10.1176\/appi.ajp.2021.21030277","journal-title":"Am J Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.05.116","article-title":"The association between ketamine and esketamine with alcohol and substance misuse: reports to the Food and Drug Administration adverse event reporting system (FAERS)","volume":"360","author":"Kwan AT","year":"2024","unstructured":"Kwan AT, Rosenblat JD, Mansur RB, Teopiz KM, McIntyre RS. The association between ketamine and esketamine with alcohol and substance misuse: reports to the Food and Drug Administration adverse event reporting system (FAERS). J Affect Disord. 2024, 360:421-426. 10.1016\/j.jad.2024.05.116","journal-title":"J Affect Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1329436","article-title":"Comparing the adverse effects of ketamine and esketamine between genders using FAERS data","volume":"15","author":"Yang X","year":"2024","unstructured":"Yang X, Chen D. Comparing the adverse effects of ketamine and esketamine between genders using FAERS data. Front Pharmacol. 2024, 15:1329436. 10.3389\/fphar.2024.1329436","journal-title":"Front Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1997.10400185","article-title":"Ketamine psychedelic therapy (KPT): a review of the results of ten years of research","volume":"29","author":"Krupitsky EM","year":"1997","unstructured":"Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs. 1997, 29:165-183. 10.1080\/02791072.1997.10400185","journal-title":"J Psychoactive Drugs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2007.10399860","article-title":"Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence","volume":"39","author":"Krupitsky EM","year":"2007","unstructured":"Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007, 39:13-19. 10.1080\/02791072.2007.10399860","journal-title":"J Psychoactive Drugs"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2013.00071","article-title":"Meditative movement for depression and anxiety","volume":"4","author":"Payne P","year":"2013","unstructured":"Payne P, Crane-Godreau MA. Meditative movement for depression and anxiety. Front Psychiatry. 2013, 4:71. 10.3389\/fpsyt.2013.00071","journal-title":"Front Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2025.03.011","article-title":"Beneficial effects of Esketamine on Morphine preference reacquisition in male rats","volume":"573","author":"Fontoura MB","year":"2025","unstructured":"Fontoura MB, Oliveira da Rosa JL, Rossato DR, et al.. Beneficial effects of Esketamine on Morphine preference reacquisition in male rats. Neuroscience. 2025, 573:120-126. 10.1016\/j.neuroscience.2025.03.011","journal-title":"Neuroscience"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252626","article-title":"S-ketamine in patient-controlled analgesia reduces opioid consumption in a dose-dependent manner after major lumbar fusion surgery: a randomized, double-blind, placebo-controlled clinical trial","volume":"16","author":"Brinck EC","year":"2021","unstructured":"Brinck EC, Virtanen T, M\u00e4kel\u00e4 S, et al.. S-ketamine in patient-controlled analgesia reduces opioid consumption in a dose-dependent manner after major lumbar fusion surgery: a randomized, double-blind, placebo-controlled clinical trial. PLoS One. 2021, 16:e0252626. 10.1371\/journal.pone.0252626","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116125","article-title":"IN Esketamine and IV Ketamine: results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression","volume":"340","author":"Gutierrez G","year":"2024","unstructured":"Gutierrez G, Swainson J, Ravindran N, et al.. IN Esketamine and IV Ketamine: results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression. Psychiatry Res. 2024, 340:116125. 10.1016\/j.psychres.2024.116125","journal-title":"Psychiatry Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/437155-evaluation-of-current-evidence-on-the-efficacy-of-esketamine-in-treating-substance-use-disorders-in-patients-with-treatment-resistant-depression-trd-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T13:18:17Z","timestamp":1773494297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/437155-evaluation-of-current-evidence-on-the-efficacy-of-esketamine-in-treating-substance-use-disorders-in-patients-with-treatment-resistant-depression-trd-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.105219","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,14]]}}}